Table 3.
Clinical trials for intellectual disability in individuals with Down syndrome.
| “A Study of RG1662 in Adults and Adolescents With Down Syndrome (CLEMATIS)” (ClinicalTrials.gov Identifier: NCT02024789) |
| https://clinicaltrials.gov/ct2/show/NCT02024789 |
| “A Study of RG1662 in Individuals With Down Syndrome” (ClinicalTrials.gov Identifier: NCT01436955) |
| https://ClinicalTrials.gov/show/NCT01436955 |
| “Down Syndrome Memantine Follow-up Study” (ClinicalTrials.gov Identifier: NCT02304302) |
| https://clinicaltrials.gov/ct2/show/NCT02304302?cond=%22Down+Syndrome%22&rank=40 |
| “Efficacy and Safety of Memantine Hydrochloride in Enhancing the Cognitive Abilities of Young Adults With Down Syndrome” (ClinicalTrials.gov Identifier: NCT01112683) |
| https://ClinicalTrials.gov/show/NCT01112683 |
| “Memantine and Down's Syndrome” (ClinicalTrials.gov Identifier: NCT00240760) |
| https://ClinicalTrials.gov/show/NCT00240760 |
| “Down Syndrome Memantine Follow-up Study” (ClinicalTrials.gov Identifier: NCT02304302) |
| https://ClinicalTrials.gov/show/NCT02304302 |
| “Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome—Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial” (ClinicalTrials.gov Identifier:NCT00675025). https://clinicaltrials.gov/ct2/show/record/NCT00675025?term=%22down+syndrome%22+AND+%22clinical+trial%22&rank=4 |
| “Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10” (ClinicalTrials.gov Identifier: NCT00754013) |
| https://ClinicalTrials.gov/show/NCT00754013 |
| “Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In Treating Cognitive Dysfunction Exhibited By Children With Down Syndrome” (ClinicalTrials.gov Identifier: NCT00570128) |
| https://ClinicalTrials.gov/show/NCT00570128 |
| “Rivastigmine Study in Adolescents With Down Syndrome (DS-Riv)” (ClinicalTrials.gov Identifier: NCT01084135) |
| https://clinicaltrials.gov/ct2/show/NCT01084135?term=down+syndrome&rank=35 |
| “Efficacy of Rivastigmine in Patients With Down Syndrome” (ClinicalTrials.gov Identifier: NCT00748007) |
| https://ClinicalTrials.gov/show/NCT00748007 |
| “Egcg, a dyrk1a Inhibitor as Therapeutic Tool for Reversing Cognitive Deficits in Down Syndrome Individuals” (ClinicalTrials.gov Identifier: NCT01394796) |
| https://clinicaltrials.gov/ct2/show/NCT01394796 |
| “Normalization of dyrk1A and APP Function as an Approach to Improve Cognitive Performance and Decelerate AD Progression in DS Subjects: Epigallocatechin Gallate as Therapeutic Tool” (ClinicalTrials.gov Identifier: NCT01699711) |
| https://ClinicalTrials.gov/show/NCT01699711 |
| “Vitamin E in Aging Persons With Down Syndrome” (ClinicalTrials.gov Identifier: NCT00056329) |
| https://clinicaltrials.gov/ct2/show/NCT00056329 |
| “Multicenter Vitamin E Trial in Aging Persons With Down Syndrome” (ClinicalTrials.gov Identifier: NCT01594346) |
| https://ClinicalTrials.gov/show/NCT01594346 |
The clinical trials reported investigate the efficacy of RG1662 (a GABAAα5 negative allosteric modulator), memantine (antagonist of the NMDA receptor), Donepezil (AChE inhibitor), Rivastigmine (AChE inhibitor), EGCG (Inhibitor of DYRK1A kinase), and Vitamin E (Antioxidant) on cognitive performance in children or adults with Down syndrome.